A pre-clinical stage biotechnology company, Nuerovation Labs Inc organizes around anxiety disorders with a particular a emphais on posttraumatic stress disorder (PTSD). Anchored in research previously undertaken by the firm's founders addressing the cause of PTSD on a physiological level, it was determine that the condition may be manifested through enduring increases in a certain protein (glutamate receptor subunit GluA1 or GRIA1) in the basolateral amygdala - region of the brain central to fear learning. Increase that protein serves to provide one of several possible objective indicators of PTSD, cognition, and a variety of other neurological states. Discovery came out of investigation using an animal model of some components of PTSD in rodents, acute stress-enhanced fear learning (SEFL).
